{"efta_number": "EFTA01125288", "page_count": 2, "url": "https://epstein-data.com/EFTA01125288", "pdf_url": "https://epstein-data.com/pdf/EFTA01125288.pdf", "pages": [{"efta_number": "EFTA01125288", "page_number": 0, "text_content": "Science Financier .leffrev Epstein Funds Pivotal Breast Cancer Research at Mount Sinai \nBreast cancer still affects 12% of women in the United States. Huge strides have been made in \nthe field of inhibitor drugs but long term survival beyond 5 years for stage IV breast cancer is \nstill only 22%. Early detection of breast cancer therefore, is essential. Recently, the Jeffrey \nEpstein VI Foundation has backed critical new research in early diagnosis. \nThe research conducted at Mount Sinai Hospital in New York City, under the direction of \nsurgeon Dr. Jess Ting, breast oncologist, Dr. Kerin Adelson and molecular biologist, Dr. Doris \nGermain, shows how metastasis is not necessarily intrinsic to the tumor but to its micro-\nenvironment. The shift in focus is critical Dr. Ting explains because it will be an effective way to \nidentify and stratify those at high risk of metastasis after surgery. \nThe Jeffrey Epstein VI Foundation that funded this research was founded by New York financier \nand science investor Jeffrey Epstein. Known for establishing the Program for Evolutionary \nDynamics at Harvard is 2003, the foundation backs a substantial amount of cutting edge cancer \nresearch across the country. \nTo obtain a breast tumor's micro-environment, Dr. Ting and his team use a unique method of \nanalyzing the fluid emitted from a post-surgery wound site. To date, clinical analysis of a \ncancer's environment has been the blood, a rich source of disease-related biomarkers. However, \nblood's complex composition, amongst other factors, is a major challenge for biomarker assays. \nOther body fluids, including urine, cerebrospina, bronchoalveolar lavage, synovial, amniotic, \nseminal plasma and interstitial fluids are also rich in disease biomarkers. However, these fluids \nare only informative in advanced metastatic cancer patients and so their prognostic value in term \nof disease progression is limited. \nDr. Ting's team saw that wound fluid (emitted from a draining tube), contains all the proteins, \ngrowth factors and cytokines that are secreted by the cells around the cancer and is an ideal way \nof studying the microenvironment in vivo. Furthermore, wound fluid from a breast cancer patient \noften has the tremendous advantage of having an exact control specimen since the non-cancerous \nbreast is often removed as a precaution and wound fluid from that breast can be compared. \nEFTA01125288\n", "char_count": 2412}, {"efta_number": "EFTA01125288", "page_number": 1, "text_content": "Over the last year, Dr. Ting and his team have found distinct differences between cancerous \nwound fluid and non-cancerous both in test tubes and in mice. It is these differences that will be \ncritical biomarkers in determining risk of future metastasis. \n\"Identifying post-surgery patients at high risk of metastasis is vital,\" Jeffrey Epstein remarked. \n\"It will be a key factor in prioritizing them for constant vigilance.\" \nJeffrey Epstein is a former member of the Trilateral Commission, the Council on \nForeign Relations and the New York Academy of Science. He is actively involved \nin the Santa Fe Institute and the Theoretical Biology Initiative at the Institute \nfor Advanced Study in Princeton. He recently sat on the Mind, Brain and Behavior \nAdvisory Committee at Harvard University. \nSOURCE: \nwww.jeffreyepsteinscience.com \nEFTA01125289\n", "char_count": 850}]}